MRCM
LUCD icon

M&R Capital Management’s Lucid Diagnostics LUCD Stock Holding History

M&R Capital Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$20 Hold
25
– – ﹤0.01% 579
2024
Q2 		$21 Hold
25
– – ﹤0.01% 546
2024
Q1 		$20 Buy
+25
New +$32 ﹤0.01% 547

Other funds holding LUCD

LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

M&R Capital Management's LUCD Position: Q3 2024 in Review

M&R Capital Management held its Lucid Diagnostics (LUCD) position steady in Q3 2024 at 25 shares worth $20. The position accounts for ﹤0.01% of the portfolio, ranked #579.

M&R Capital Management first reported a position in LUCD in Q1 2024 and has held it in 3 quarters since. The position peaked at $21 in Q2 2024. 29 funds tracked by Wall St. Rank hold LUCD as of Q3 2024.

  • M&R Capital Management held 25 shares of Lucid Diagnostics worth $20 as of Q3 2024.
  • M&R Capital Management left its Lucid Diagnostics share count unchanged in Q3 2024.
  • Lucid Diagnostics made up ﹤0.01% of M&R Capital Management's portfolio in Q3 2024, its #579 holding.
  • M&R Capital Management first reported a position in Lucid Diagnostics in Q1 2024 and has held it in 3 quarters since.
  • M&R Capital Management's Lucid Diagnostics position peaked at $21 in Q2 2024.
  • 29 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2024.

Based on M&R Capital Management's 13F filing for Q3 2024, filed 2 Oct 2024.